Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 573K 524K 478K 901K 60.05M 929K 6.31M 2.52M 32.04M 2.4M 2.35M 101M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.46M 15.96M 14.57M 27.44M 1.83B 28.31M 192M 76.69M 976M 73.07M 71.5M 3.08B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI
20-05-29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
20-04-22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-04-21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
20-03-30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-01-08	Motion for Asset Sale Approved for Achaogen, Inc.	CI
19-12-29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
19-09-24	Final DIP Financing Approved for Achaogen, Inc.	CI
19-08-29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
19-08-13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
19-07-29	Achaogen, Inc. Announces Management Changes	CI
19-07-23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 10.02M 9.16M 8.36M 15.75M 1.05B 16.25M 110M 44.03M 561M 41.95M 41.05M 1.77B	8.73M 7.83M 7.15M 6.53M 12.3M 820M 12.69M 86.23M 34.39M 438M 32.76M 32.06M 1.38B
Net income	-126M -113M -103M -93.99M -177M -11.81B -183M -1.24B -495M -6.3B -472M -461M -19.89B	-187M -167M -153M -140M -263M -17.53B -271M -1.84B -735M -9.36B -700M -685M -29.53B
Net Debt	-143M -128M -117M -107M -201M -13.43B -208M -1.41B -563M -7.16B -536M -525M -22.62B	18.83M 16.89M 15.43M 14.09M 26.54M 1.77B 27.38M 186M 74.18M 944M 70.67M 69.16M 2.98B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile